Positive Phase III data will support supplemental FDA application for Eylea

20 March 2018

Regeneron Pharmaceuticals (Nasdaq: REGN) has released positive data from the Phase III PANORAMA trial evaluating Eylea (aflibercept) in certain diabetic retinopathy patients.

The trial met its 24-week primary endpoint, with 58% of the test group experiencing a two-step or greater improvement from baseline according to a commonly-used measure. This compares with 6% for the sham group.

Regeneron, which has invested in further clinical trials including one to test a new quarterly dosing regimen, is in competition with Novartis (NOVN: VX) and Roche (ROG: SIX), who are testing rival candidates brolucizumab and RG7716, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK